Oruka Therapeutics, Inc. ( (ORKA) ) has released its Q3 earnings. Here is a breakdown of the information Oruka Therapeutics, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, focuses on developing biologics for psoriasis and other inflammatory and immunology indications. In its latest earnings report for the quarter ended September 30, 2025, Oruka Therapeutics highlighted significant financial activities, including a substantial increase in cash and marketable securities, driven by successful private placements and financing activities. The company reported a net loss of $30.3 million for the quarter, with total operating expenses reaching $34.1 million, primarily due to research and development costs. Despite the losses, Oruka’s financial position remains strong with $500.9 million in cash, cash equivalents, and marketable securities, providing a solid foundation for ongoing and future research endeavors. Looking ahead, Oruka Therapeutics’ management remains optimistic about its financial health, expecting existing resources to support operations for at least the next twelve months while continuing to invest in research and development to advance its product pipeline.